Novo Nordisk CEO Mike Doustdar is under pressure from investors to restore confidence in the company’s growth prospects. The Danish drugmaker recently raised its full-year profit and sales outlook but disappointed investors with a narrow sales miss for its new Wegovy pill and a trial setback for its next-generation obesity drug CagriSema.
Investor Concerns
Investors are looking for details on the company’s pipeline and its ability to develop new medicines beyond obesity and diabetes. The CagriSema results marked the latest setback following earlier trial disappointments, adding to investor concerns over Novo’s next-generation obesity medicines.
The company’s U.S.-listed ADRs slipped 6%, indicating a likely fall when the stock opens in Copenhagen. The shares, which had been rallying since March, are down 5% this year.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.